Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine

(2011) Maite Verreault et al.   BMC CANCER

PET–CT for radiotherapy treatment planning and response monitoring in solid tumors

(2011) Johan Bussink et al.   Nature Reviews Clinical Oncology

Hypoxia and Radiation Therapy: Past History, Ongoing Research, and Future Promise

(2009) Sara Rockwell et al.   CURRENT MOLECULAR MEDICINE

Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target

(2009) Stina Häggström Rudolfsson et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer

(2008) Roberto Petrioli et al.   CANCER TREATMENT REVIEWS

Hypoxia in prostate cancer: A powerful shield against tumour destruction?

(2008) L. Marignol et al.   CANCER TREATMENT REVIEWS

Molecular Imaging of Hypoxia

(2008) K. A. Krohn et al.   JOURNAL OF NUCLEAR MEDICINE